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Summary In this study, we compared the cellular uptake,
intracellular localization and cytotoxicity of two groups of
anthracycline derivatives in cultured H9c2(2-1) rat
cardiomyoblasts. The first group consisted of doxorubicin
(DOX) and two of its derivatives containing a formamidino
group (–N=CH–N<) at the C-3′ position with a morpholine
(DOXM) or a hexamethyleneimine (DOXH) ring. The second
group consisted of daunorubicin (DRB) and its derivatives
containing a morpholine (DRBM) or a hexamethyleneimine
(DRBH) ring. DOXH and DRBH were taken up by
cardiomyoblasts more efficiently than estimated for other test-
ed anthracyclines. The cellular uptakes of DOXM and DRBM
were reduced compared to those of the parent compounds.
Applied structural modifications of DOX andDRB influenced
the subcellular localization of the tested derivatives. DOX and
DOXH were localized primarily in nuclei, whereas the other
anthracyclines were found in the nuclei and cytoplasm. The
percentages of the compounds that accumulated in the nuclei
were 80.2 and 54.2 % for DOX and DOXH, respectively. The
lowest nuclear accumulation values were observed for DRBM
(19.9 %), DRBH (21.9 %) and DOXM (23.7 %). The ability
of anthracyclines to accumulate in the nuclei correlated with
their DNA binding constants (r=0.858, P=0.029). A correla-
tion was found between the accumulation of the tested
anthracyclines in the nuclei of cardiomyoblasts and their
cardiotoxicity in vivo, which was observed in our previous
study. We suggest that cytotoxicity and the anthracycline ac-
cumulation level in the nuclei of cultured cardiomyoblasts
could be used for early prediction of their cardiotoxicity.
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Abbreviations
DOX doxorubicin
DOXM doxorubicin containing a formamidino group with
a morpholine ring
DOXH doxorubicin containing a formamidino group with
a hexamethyleneimine ring
DRB daunorubicin
DRBM daunorubicin containing a formamidino group with
a morpholine ring
DRBH daunorubicin containing a formamidino group with
a hexamethyleneimine ring
Introduction
Anthracyclines have received significant attention due to their
effectiveness and extensive use as anticancer agents. At pres-
ent, the clinical use of these drugs is offset by drug resistance
in tumors and cardiotoxicity [1, 2]. One of the many possible
strategies for improving the therapeutic effectiveness of
anthracyclines is the synthesis of new analogs with modified
structures. Structural modifications of the anthracycline mol-
ecule may change many biological properties of these drugs,
such as cellular uptake, subcellular localization, and cellular
target affinity, which may affect the drugs’ selectivity toward
cancer cells [3]. Modifications at the C-3′ position of the
daunosamine moiety of anthracycline may result in
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improvement of some biological properties that are important
for the anticancer action of these compounds [4–7].
Formamidinoanthracyclines are a new group of chemically
modified anthracyclines. The most important feature of this
novel class of anthracyclines is their lower cardiotoxicity com-
pared to that of the parent compounds; this lower
cardiotoxicity has been demonstrated in animal models [4,
8]. Although the low cardiotoxicity of these compounds
seems to be a very promising feature, how modification of
the daunosamine group of anthracycline at the C-3′ position
produces this effect remains unclear. One possible method to
reduce the cardiotoxicity of anthracyclines may be to reduce
their accumulation in cardiac cells.
Heart tissue was demonstrated to have a small subpopula-
tion of immature myocytes produced by stem-like cells [9,
10]. Such cycling cardiogenic precursors may be more sensi-
tive to antiproliferative drugs than terminally differentiated
cardiomyocytes, and their drug-induced death may play an
important role in the cardiotoxic effects of anthracyclines
[11]. Therefore, cardiac myoblasts in the form of rat
embryonic H9c2(2-1) cells may be a goodmodel for assessing
the cardiotoxic properties of potential anticancer agents.
In this study, we attempted to determine whether the cyto-
toxicity of some doxorubicin (DOX) and daunorubicin (DRB)
analogs, which were modified in the daunosamine moiety at
the C-3′ position by the introduction of a formamidino group
containing a morpholine or hexamethyleneimine ring (see
Fig. 1 for structures), in cultured rat cardiomyoblasts is related
to their cellular uptake and cellular localization.
Materials and methods
Drugs
DOX, DRB and their derivatives containing a formamidino
group with a morpholine ring (DOXM and DRBM) or a
hexamethyleneimine ring (DOXH and DRBH) were synthe-
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anthracyclines
Invest New Drugs (2015) 33:1032–1039 1033
Warsaw [12]. Anthracyclines and their derivatives were dis-
solved in water and used immediately for each experiment.
Cell lines and cell culture
Rat DB1X cardiomyoblasts (H9c2(2-1) were purchased from
the European Collection of Cell Cultures (ECACC). The cells
were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10 % heat-inactivated fetal calf serum and
2 mM glutamine (all from Sigma-Aldrich) in a humidified
5 % CO2 atm at 37 °C. The cells were maintained as recom-
mended by the supplier at a low density to avoid confluency
and myoblast loss. All experiments were performed using
cells at passages 4–27.
Cytotoxicity assay
The cytotoxic activity of the drugs was assayed by measuring
their inhibitory effects on H9c2(2-1) cell proliferation. To
measure the cytotoxicity of doxorubicin, daunorubicin, and
their analogs, the tetrazolium dye method was used [13].
Cells were seeded at 1×104 cells/well in 48-well plates.
After 24 h, the cells were incubated with different concentra-
tions of anthracyclines for 72 h in triplicate in a final volume
of 1 ml. Then, 50 μl of a sterile aqueous solution of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide
(5 mg/ml) (Sigma-Aldrich) was added to each well for an
additional 3 h. The blue formazan precipitate was dissolved
in DMSO (Sigma-Aldrich), and the absorbance of solutions
was measured at 540 nm. For each experiment, determinations
were performed in three replicates. The IC50 values (the
anthracycline concentration effective at inhibiting cell growth
after exposure to the drug for 72 h) were read from survival
curves, which were fitted to an exponential equation using
Xact v. 7.2, a statistical software tool by SciLab (Germany).
Cell cycle analysis
The cell cycle was analyzed by flow cytometry using a
Becton-Dickinson FACSCanto II flow cytometer. H9c2(2-1)
cells were seeded at 1×104 cells/cm2 in 10 cm2 culture flasks.
After the cells were allowed to grow for 24 h, the mediumwas
replaced and the cells were treated with an equitoxic
anthracycline concentration corresponding to IC50.
Treatment was performed for 24 h, and then the cells were
washed in PBS and trypsinized. After the cells were washed in
PBS again, they were fixed in 70 % ethanol and incubated for
1 h on ice. Fixed cells were washed twice in PBS, resuspended
in commercially available propidium iodide staining solution
and then subjected to flow cytometric assay. The percentages
of H9c2(2-1) cells present in G1, S, and G2 phases of the cell
cycle after drug treatment were analyzed using FACSDiva 6.1
software.
Cellular uptake
Anthracycline uptake was estimated by fluorimetric measure-
ments after the drugs were extracted with an ethanol/HCl mix-
ture as described by Riganti et al. [14]. H9c2(2-1) cells (2×105)
were seeded onto 40×11 mm tissue culture dishes for 24 h.
Then, the cells were treated in growth medium with 10 μM
anthracycline solution at 37 °C for 1 h. After this time, the cells
were gently scraped and suspended in 5 ml of ice-cold PBS.
The cell suspension aliquots were centrifuged at 1500 rpm for
5 min and then washed twice in ice-cold PBS. Next, cell pellets
were collected and resuspended in 2 ml of a 1:1 mixture of
ethanol:0.3 M HCl, and the fluorescence intensities of these
suspensions were measured at 20 °C using a Perkin-Elmer LS
55 spectrofluorimeter. The optimal excitation and emission
wavelengths were 485 and 590 nm, respectively. To estimate
the drug concentrations, calibration curves in the concentration
range of 0.01–0.5 μMwere prepared. Because the fluorescence
was quenched slightly in the presence of cells, each point of the
calibration curves was measured in the presence of 2×105 cells
suspended in a mixture of ethanol/HCl.
Subcellular localization of anthracyclines
The subcellular localization of DOX, DRB and their analogs
was examined using an Olympus BX-43 fluorescence micro-
scope. H9c2(2-1) cells (2×104) were seeded onto 40×11 mm
tissue culture dishes for 24 h. Then, the cells were incubated
for 1 h at 37 °C in 2 ml of fresh growth medium supplemented
with 10 μM drug. After incubation, the cells were washed in
4 ml of cold PBS, covered with a 24-mm cover glass, and
observed at 400-fold magnification in visible light (dark field)
and after excitation with a wide green filter. Cell images were
acquired with an Olympus DP50 camera using the same ex-
posure parameters for each image and saved in TIFF format as
RGB images. Cell images were then processed by graphic
software (Micrografx Picture Publisher v. 10) to prepare im-
ages suitable for densitometric measurements. First, the red
channel for each image was separated and inverted to obtain
images where areas corresponding to high fluorescence inten-
sity became dark. Then, the part of the cell image correspond-
ing to the nucleus was cut off and transferred above the part
corresponding to the cytoplasm. This method allowed an im-
age consisting of the separated nucleus and cytoplasm to be
obtained. Such an image was then used as a path for densi-
tometry. To estimate the percentages of drugs localized in the
cytoplasm and in the nucleus, densitometric analysis was per-
formed using GelScan v. 1.45 software (Kucharczyk T.E.).
Affinity of anthracyclines to DNA
The binding of the anthracyclines to double-stranded calf thy-
mus DNA was tested by the ethidium bromide displacement
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assay [15]. This method is based on the competition between
the tested compound and ethidium bromide for DNA interca-
lation sites. The fluorescence intensity of ethidium bromide
increases upon DNA binding. Addition of a compound
displacing intercalated ethidium bromide leads to quenching
of the fluorescence of the DNA/ethidium bromide complex.
The percentage of initial fluorescence was plotted against the
concentration of the added compound, and the IC50 value was
read. The IC50 value is defined as the concentration of added
compound required to reduce the fluorescence of the DNA/
ethidium bromide complex to 50 %. IC50 values were then
used to calculate the apparent binding constants of the
anthracyclines to DNA.
Statistical analysis
The data were analyzed using the SigmaPlot v. 12.5 statistics
package (Systat Software, Inc. Chicago, USA). All the values
in this study were expressed as the mean±SD from at least
three independent experiments. If no significant differences
were detected between variances as assessed by the
Snedecor–Fisher test, then the differences were compared by
two-tailed Student’s t-test. The results were considered signif-
icant when P<0.05. The relation between the DNA binding
constants and nuclear localization of the anthracyclines was
assessed by linear regression analysis.
Results
Cytotoxic activities of anthracyclines
The cytotoxicity potencies of DOX, DRB, and their analogs in
H9c2(2-1) rat cardiomyoblasts exposed to the drugs for 72 h
are presented in Table 1. All the tested anthracyclines were
effective in inhibiting H9c2(2-1) cell proliferation. The IC50
values measured for doxorubicin and its derivatives were in
the range of 35–138 nM. The most toxic compound in this
group was the parent compound DOX, which exhibited ap-
proximately 4 times higher cytotoxic activity than DOXMand
2.5 times higher than DOXH. The IC50 values for daunorubi-
cin derivatives were in the range of 75–626 nM. In this series
of anthracyclines, the parent daunorubicin was the most cyto-
toxic drug, exhibiting 8 and 2 times higher activity compared
to its analogs DRBM and DRBH, respectively.
Cell cycle analysis
Cell cycle analysis by flow cytometry was performed 24 h
after cardiomyoblasts were treated with anthracyclines. The
concentration of each drug that inhibited 50 % proliferation
of cultured H9c2(2-1) cells was selected for these experi-
ments. The results of the cell cycle analysis are shown in
Fig. 2. The population of untreated control cells contained
primarily 2 N content of DNA corresponding to G0/G1 phase
(80.1 %). The S and G2/M fractions were 11 and 8.7 %, re-
spectively. Of the H9c2(2-1) cells treated with DOX, 40.6 %
showed increased accumulation in G2/M phase of the cell
cycle and decreases in G0/G1 and S-phase populations com-
pared with the untreated control. A different effect on the
cycling of H9c2(2-1) cells was observed when cells were
treated with DOXM and DOXH. These compounds induced
increases in the S phase fraction (33.5 and 36.4 % for DOXM
and DOXH, respectively). The accumulation of cells in S
phase was accompanied by a decline in the G0/G1 population
(53.5 and 50.1 % for DOXM and DOXH, respectively) and a
slight increase in the percentage of cells in G2/M phase com-
pared with untreated cells. Extremely similar results were ob-
tained for DRB and its formamidine derivatives. DRB-
induced cell cycle G2/M arrest resembled the arrest caused
by DOX, whereas DRBM and DRBH produced extremely
similar patterns of S phase arrest as observed for DOXH and
DOXH (data not shown).









DOX 35±4 890±42 80.2±3.1 18.1±0.41 -0.644
DOXM 138±18 < 0.001 690±21 23.7±1.0 0.90±0.12 -0.995
DOXH 87±7 < 0.001 1330±120 54.2±6.2 7.30±0.14 1.459
DRB 76±7 3230±153 35.8±4.1 11.7±0.22 -1.344
DRBM 626±18 < 0.001 618±51 19.9±1.4 0.64±0.03 -0.791
DRBH 172±14 < 0.001 5640±168 21.9±2.1 4.1±0.08 0.758
Cytotoxicity was determined by MTT assay. All IC50 values are the means of six independent experiments±S.D. P values refer to the significances of
differences between parent compounds and their analogs as analyzed by Student’s t-test. The data for cellular uptake are the means of 7 independent
experiments±S.D. The data presenting the % of drug in the nucleus are the means of 25 estimations for individual cells±S.D. The DNA binding constant
values are presented as the means of three independent estimations±S.D. */logP is the partition coefficient calculated by Chem3D Ultra v. 6 software
(Cambridge Soft).
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Uptake of anthracyclines by rat cardiomyoblasts
The derivatives were taken up by H9c2(2-1) cells at differ-
ent rates than those for their parent anthracyclines. Their
uptake levels, expressed in nanomoles of compound per
1×106 cells, are shown in Table 1. Cellular accumulation
of DOX was approximately 30 % higher than its derivative
containing a morpholine ring (DOXM). DOXH was
transported into the cells more efficiently than DOX and
DOXM. The accumulation of DOXH in cardiac myoblasts
was almost 2 times higher than that of DOXM and 1.5
times higher than that of the parent doxorubicin. The most
Bpenetrating^ compound from the entire group of exam-
ined analogs was the daunorubicin derivative with a
hexamethyleneimine ring (DRBH); its accumulation in
H9c2(2-1) cells was the highest among all tested drugs.
After the cells were incubated with this compound for
1 h, the level of accumulation of this compound was more
than 1.5 times higher than that of the parent drug (DRB)
and at least 5–7 times higher than that of other tested com-
pounds. Our experiments provided conclusive evidence
that the hexamethyleneimine moiety enhances the uptake
of anthracycline derivatives (DOXH and DRBH) by
H9c2(2-1) cells. The lowest uptake values were found for
both formamidino derivatives containing a morpholine
ring (DOXM and DRBM). The lower cellular uptake
values of these compounds translated into decreases in
their cytotoxic potency in H9c2(2-1) cells (Table 1).
Subcellular localization of anthracyclines in rat
cardiomyoblasts
The fluorescence microscopy images of H9c2(2-1) cells incu-
bated with the compounds are presented in Fig. 3. The
anthracyclines accumulated in the nuclei and in the cytoplasm,
where they appeared in the form of small granules. As shown
in Fig. 3, DOX and DOXH accumulated preferentially in cell
nuclei. DOXM exhibited a different preference for subcellular
compartments. The red fluorescence corresponding to DOXM
was found primarily in the cytoplasm, whereas nuclear chro-
matin was stained much more weakly. DRB was present in
both the nucleus and cytoplasm, whereas its formamidine de-
rivatives DRBM and DRBH were localized primarily in the
cytoplasm.
To estimate the percentages of anthracyclines localized
in the nucleus and in the cytoplasm of myocardial cells,
densitometric quantification was performed. As shown in
Table 1, the highest percentage of drug localized in cell
nuclei, 80.2 %, was measured for DOX. DOXH exhibited
a lower affinity to nuclear chromatin and to the cytoplasm
compared to DOX (54.2 % of the DOXH drug was local-
ized in nuclei). All other compounds exhibited the ability
to accumulate in the cytoplasm rather than in nuclei. In
particular, low affinity to nuclear chromatin was found
for the morpholine derivatives DOXM and DRBM as well





























































cardiomyoblasts arrest in G2/M
and S phases after anthracycline
treatment. Cells were treated for
24 h with equitoxic
concentrations of each drug that
inhibited 50 % proliferation of
cells and were subjected to flow
cytometric analysis
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Correlation between the affinity of anthracyclines to DNA
and their localization in the nuclei of rat cardiomyoblasts
The DNA binding constant (Kapp) values estimated by the
ethidium bromide displacement assay are shown in Table 1.
The parent compounds DOX and DRB exhibited the highest
affinities to double-stranded calf thymus DNA. Kapp values
for their derivatives possessing a hexamethyleneimine ring
(DOXH and DRBH) were 2.5–2.8 times lower. The lowest
affinities to DNA were found for the morpholine derivatives
DOXM and DRBM. When compared to the parent drugs,
their Kapp values were approximately 20 times lower. When
we plotted the percentage of anthracyclines localized in the
nucleus against their Kapp values and performed a linear re-
gression analysis, a significant correlation was found (r=
0.858, P=0.029; Fig. 4). Thus, this result indicates that
anthracyclines having high affinity to DNA are transported
preferably into nuclei.
Discussion
The delivery and subcellular localization of drugs are impor-
tant factors that influence their biological activity. Other au-
thors have noted that the cytotoxic activity and clinical effica-
cy of anthracyclines may strongly correlate with their uptake
potency and subcellular distribution [3, 16–19]. In this study,
we used cultured rat cardiomyoblasts to compare the uptake,
subcellular localization and cytotoxic activity of four
anthracycline derivatives and two parent drugs. Our results
show that the introduction of a formamidino group with a
morpholine or hexamethyleneimine ring at C-3′ of
daunosamine reduces the affinity of the tested anthracycline
analogs to DNA aswell as their cellular uptake and subcellular
localization (Table 1). These results confirm the finding of
Shaul et al. [3], who found that even small structural changes
in the anthracycline molecule affects its cytotoxic activity and
subcellular localization. The enhanced uptake of DOXH and
DRBH by rat cardiomyoblasts can be explained by their lipo-
philicity, as the logP values of these derivatives are signifi-
cantly higher than are those for DOX and DRB (Table 1). This
observation is consistent with the findings of other authors
who reported the strong impact of lipophilicity on the level
of anthracycline accumulation in mammalian cells [16, 18,
19]. We assume that cell morphology is a very important fac-
tor that influences drug accumulation. In cardiomyoblasts that
contain a large cytoplasm compartment (Fig. 3), the analogs
accumulated in the cytoplasm, in contrast to the parent
anthracyclines, which were transported preferentially to the
nuclei. Our data suggest that cells containing large cytoplasm
compartments and small nuclei accumulate hydrophobic
anthracyclines preferentially, whereas the hydrophobicities
of these drugs are less important for drug accumulation in cells
with very large nuclei and small cytoplasmic compartments,
e.g., leukemia cells [20].
Cell cycle analysis revealed that the compounds varied in
their mode of cytotoxic action (Fig. 2). The growth inhibitory
effect of DOX and its formamidine derivatives on cultured
Fig. 3 Images of H9c2(2-1) cells
incubated with 10 μM
anthracycline for 1 h at 37 °C.
Cells were observed at 400-fold
magnification after excitation
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Fig. 4 Correlation between the percentage of anthracyclines localized in
the nuclei of H9c2(2-1) cells and their DNA binding constants (Kapp).
Correlation coefficient r=0.858, P=0.029. Horizontal and vertical bars
represent the standard deviation values
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cardiomyoblasts appears to be due to blocks at G2/M phase
(DOX) and G1/S phase (DOXM and DOXH) of the cell cycle.
The same results were obtained for DRB, DRBM and DRBH
(data not shown). This result is not surprising because our
earlier studies demonstrated that formamidinoanthracyclines
are not topoisomerase II inhibitors. These compounds produce
different patterns of DNA damage than do their parent com-
pounds, possibly mediated by a free radical mechanism [6, 7],
whereas DOX and DRB are known to stabilize the Bcleavable
complex^ of this enzyme with DNA [6, 7, 22].
The structures of the anthracyclines influenced their intra-
cel lular distr ibution. The morpholine as well as
hexamethyleneimine substituents reduced the ability of the
anthracyclines to bind to nuclear components (Fig. 3 and
Table 1). This effect may be explained by the different affin-
ities of the tested anthracyclines to DNA. When the percent-
ages of anthracyclines localized in the nucleus was plotted
against their DNA -binding constants, a significant correlation
was found (r=0.858, P=0.029; Fig. 4). Derivatives exhibiting
low affinity to DNAmay accumulate with higher efficiency in
the cytoplasm, as cytoplasmic components such as RNAmol-
ecules and proteins may compete with DNA for binding of
these drugs.
Affinity to DNA seems to be a primary driving force
directing anthracycline molecules into the cell nucleus, and this
finding raises the question as to whether nuclear uptake of
anthracyclines depends on the DNA content in cells. This pos-
sibility exists, as there are cells in different cycle phases and
containing different DNA amounts in a population of
cardiomyoblasts. Such cell populations should contain cells
of different brightness after incubation with fluorescent com-
pounds. However, we did not observe any differences in cell
nuclear fluorescence when we viewed several cardiomyoblasts
at once in the viewing field at low magnification. The bright-
ness of the nuclei and cytoplasm was dependent on the type of
anthracycline derivative, as shown in Fig. 3. This result can
likely be explained by the fact that all experiments were per-
formed 24 h after seeding the cells, when the majority of cells
were at G0/G1 phase and contained 2 N DNA content (Fig. 2).
Nonetheless, this issue is important; therefore, cells that are
used to study the intracellular localization of fluorescent drugs
should be subjected to cell cycle analysis to ensure that the
majority of cells contain similar DNA content.
As mentioned in the Introduction, anthracycline analogs
with a modified daunosamine moiety (DOXM, DOXH,
DRBM and DRBH) were tested previously in animal models,
and all of them exhibited lower cardiotoxicity than did DOX
and DRB [4]. Interestingly, in this study, the same group of
analogs exhibited decreased cytotoxicity in cultured
cardiomyoblasts as well as lowered affinity to nuclear compo-
nents, presumably primarily to DNA (Table 1 and Fig. 3),
when compared to DOX and DRB. The correlation between
cytotoxicity in vitro, accumulation of the tested anthracyclines
in the nuclei of cardiomyoblasts, and their cardiotoxicity
in vivo observed in our previous work [4] leads to the hypoth-
esis that the cytotoxic potencies and the accumulation of
anthracyclines in the nuclei of cultured cardiomyoblasts may
be good and simple predictors of cardiotoxicity. This is an
attractive possibility, as reliable methods that can be used for
early prediction of anthracycline cardiotoxicity are needed
[21].
The mechanism of anthracycline cardiotoxicity in vivo is
very complex, and many cellular metabolic reactions may
play a very important role in this process. Therefore, several
possible mechanisms of anthracycline cytotoxicity are
discussed in the literature [1, 2, 22]. The relatively new con-
cept concerning anticancer drug cardiotoxicity is based on the
finding that a small fraction of proliferating cells is present in
cardiac tissue and may be a target for antiproliferative agents.
[9–11]. The results of our work support this concept, as DOX
and DRB, which exhibited the highest accumulation in cell
nuclei and were the most potent inhibitors of cardiomyoblast
proliferation among the tested compounds, were also found to
be the most cardiotoxic in an in vivo animal model.
In conclusion, considering the complexity of the problem,
we think that estimating cytotoxic activity and analyzing in-
tracellular distribution of new potential anticancer
anthracyclines in cultured cardiomyoblasts may be helpful in
their early preclinical evaluation.
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